Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-31
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was $0.00.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $100.00K.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $100.00K.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $500.00K, a 400.00% increase from fiscal 2021.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $100.00K, a 91.64% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-31 | |||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $100.00K 10-K · filed 2025-03-21 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $100.00K 10-Q · filed 2025-11-14 | |||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $100.00K 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-14 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $0.00 derived: sum of 2 quarters · filed 2024-03-22 | $0.00 derived: sum of 3 quarters · filed 2024-03-22 | $500.00K 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $500.00K 10-Q · filed 2023-11-09 | $500.00K derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $500.00K 10-Q · filed 2023-08-10 | $500.00K derived: sum of 3 quarters · filed 2023-08-10 | $500.00K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-11 | $500.00K derived: sum of 2 quarters · filed 2023-05-11 | $500.00K derived: sum of 3 quarters · filed 2023-05-11 | $500.00K derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $0.00 derived: sum of 2 quarters · filed 2023-03-27 | $0.00 derived: sum of 3 quarters · filed 2023-03-27 | $100.00K 10-K · filed 2023-03-27 | $92.19K 10-K · filed 2022-03-25 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $100.00K 10-Q · filed 2022-11-10 | $596.47K derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $100.00K 10-Q · filed 2022-08-05 | $596.47K derived: sum of 3 quarters · filed 2022-08-05 | $1.20M derived: sum of 4 quarters · filed 2022-08-05 | ||||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-12 | $596.47K derived: sum of 2 quarters · filed 2022-05-12 | $1.20M derived: sum of 3 quarters · filed 2022-05-12 | $1.20M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $496.47K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $1.10M derived: sum of 2 quarters · filed 2022-03-25 | $1.10M derived: sum of 3 quarters · filed 2022-03-25 | $1.20M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $600.00K derived: sum of 2 quarters · filed 2021-11-04 | $700.00K 10-Q · filed 2021-11-04 | |||||
| 2020-09-16 | $15.68K 10-Q · filed 2020-11-12 | |||||||
| 2020-07-14 | $623.56K 10-Q · filed 2020-11-12 | |||||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $100.00K 10-Q · filed 2021-08-05 | $92.01K 10-Q · filed 2020-08-12 | |||||
| 2020-03-31 | $100.00K 10-Q · filed 2021-05-12 | $92.01K 10-Q/A · filed 2020-05-15 | ||||||
| 2020-03-23 | $92.01K 10-Q · filed 2020-11-12 | |||||||
| 2019-12-31 | $642.36K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |